Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 48433-034

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 48433-034). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Safecor Health, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Divalproex Sodium Er Tablets, Usp 250 mg Unit Carton Label (Image 01)

Divalproex Sodium Er Tablets, Usp 250 mg Unit Carton Label (Image 01)
Divalproex Sodium Extended-Release 250 mg film-coated tablets for oral use, supporting once-daily dosing. The label includes the proprietary and generic name, strength, tablet image marked with imprint 'M 177', and indicates valproic acid activity. It specifies the quantity as 80 tablets (10 x 8) and mentions storage instructions and manufacturer information by Mylan Pharmaceuticals Inc.*
FDA Label Image

Unit Carton (Image 02)

Unit Carton (Image 02)
Packaging label for Divalproex Sodium tablets by Safecor Health, LLC. The label features the UDL logo and notes that the package is a unit dose container not child resistant, intended for institutional use. It advises keeping the product out of children's reach and mentions the container is light-resistant with a window to view lot number and expiration date. Contact information includes a phone number and website.*
FDA Label Image

Divalproex Structural Formula (Image 03)

Divalproex Structural Formula (Image 03)
Chemical structure diagram of divalproex sodium, illustrating the molecular arrangement of the compound with multiple carbon chains, sodium ion, and functional groups.*
FDA Label Image

Figure 1: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Adjunctive Therapy Stud (Image 04)

Figure 1: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Adjunctive Therapy Stud (Image 04)
A line graph comparing the percentage reduction in CPS rate versus percent of patients, showing improvement and worsening. The graph plots two lines: one for Divalproex Sodium Delayed-Release and one for placebo, indicating differences in patient response rates between the two treatments.*
FDA Label Image

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)
A line graph showing the percentage reduction in CPS rate on the vertical axis against the percentage of patients on the horizontal axis. Two curves compare high dose versus low dose divalproex sodium delayed release, with improvement and worsening indicated on the vertical axis.*
FDA Label Image

Figure 3. Mean Reduction In 4-week Migraine Headache Rates (Image 06)

Figure 3. Mean Reduction In 4-week Migraine Headache Rates (Image 06)
A bar graph comparing a numeric variable between placebo and Divalproex Sodium Extended-Release Tablets groups. The graph shows two bars, with the Divalproex Sodium bar higher than the placebo bar, annotated with a significance marker (p=0.006).*
FDA Label Image

Divalproex Sodium Er Tablets, Usp 500 mg Unit Carton Label (Image 07)

Divalproex Sodium Er Tablets, Usp 500 mg Unit Carton Label (Image 07)
Label for Divalproex Sodium Extended-Release Tablets, USP, 500 mg, film-coated, extended-release oral tablets. The label indicates once-daily dosing and a package quantity of 80 tablets (10 x 8). The product is labeled as prescription only, with valproic acid activity noted, and is manufactured by Mylan Pharmaceuticals Inc., Morgantown, WV. Storage instructions and a barcode are also visible.*
FDA Label Image

Unit Carton (Image 08)

Unit Carton (Image 08)
Packaging label for Divalproex Sodium by Safecor Health, LLC, displaying the UDL logo with instructions stating the unit dose package is not child resistant, intended for institutional use only, and includes warnings to keep out of reach of children. The label notes the container's light resistance and directs to a window for lot number and expiration date information. Contact details include Safecor Health's phone number and website.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.